ArticleNature medicine2023
Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance.
Open access · greenAbstract read
In one paragraph
Article in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 318 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
318citing papers in PubMed, 1 pooled it
71.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
318 citing papers in PubMed, 1 synthesis or guideline pooled it, 442 citations in OpenAlex.
- T cell-mediated immune function in gastric cancer: a bibliometric overview of the last 20 years (2006-2025).Frontiers in oncology · 2026Pooled it
- PRDM1+ Malignant Cells Mediate an Immunosuppressive Landscape and Resistance to Neoadjuvant Chemoradiotherapy and Immunotherapy in Esophageal Squamous Cell Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Trial
- Tumor ecosystem and microbiome features associated with efficacy and resistance to avelumab plus chemoradiotherapy in head and neck cancer.Nature cancer · 2026Trial
- Preoperative pembrolizumab (anti-PD-1 antibody) combined with chemoradiotherapy for esophageal squamous cell carcinoma: a phase 1/2 trial (PALACE-2).Signal transduction and targeted therapy · 2025Trial
- 4-1BBCell reports. Medicine · 2025Trial
- Review
- A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture.Cancer discovery · 2026Article
- Prefibrotic bone marrow microenvironment is a hallmark of clonal hematopoiesis.Nature immunology · 2026Article
- IL-23-engineered oncolytic vaccinia virus enhances pancreatic cancer control through inflammasome-driven Th17-skewed CD4Journal for immunotherapy of cancer · 2026Article
- Differential peripheral immune dynamics underlie therapeutic response to chemotherapy and chemoimmunotherapy in triple-negative breast cancer.ImmunoHorizons · 2026Article
- Rejuvenating endogenous antitumor immunity via a chimeric receptor-engineered oncolytic virus targeting tumor-associated macrophages.Science advances · 2026Article
- Cofilin1-driven cytoskeletal remodeling modulates pan-cancer CD8Cell reports. Medicine · 2026Article
- Cancer-Intrinsic Protein Neddylation Modulates the Intratumoral Immune Landscape to Constrain Immune Checkpoint Blockade Therapy.Cancer immunology research · 2026Article
- A bioinformatics analysis of KIF transcriptomic subtyping reveals prognostic heterogeneity and differential therapeutic responses in cervical cancer.Oncology letters · 2026Article
- Single-cell multi-omics dissects transcript isoform and immune repertoire dynamics in human immunosenescence.Science China. Life sciences · 2026Article
- scRNA-seq and bulk RNA-seq reveal the characteristics of macrophage copper metabolism and establish a risk signature in hepatocellular carcinoma.Translational cancer research · 2026Article
- Article
- Tumor-distal mediastinal lymph nodes harbor tumor-related progenitor exhausted T cells in lung cancer after neoadjuvant chemoimmunotherapy.Cell reports. Medicine · 2026Article
- Standardizing pCR/MPR Assessment in NSCLC After Neoadjuvant Therapy: Challenges and Perspectives.Cancers · 2026Review
- TSTScope Unifies Single-Cell Multi-Omics to Identify Functional T Cell States Predictive of Immunotherapy Response.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
258 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
45 authors at 7 institutions in 3 countries.
Yanshuo ChuDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Enyu DaiDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yating LiDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Guangchun HanDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-9277-2507
Guangsheng PeiDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Davis R IngramDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Krupa ThakkarTumour Immunogenomics and Immunosurveillance Laboratory, University College London Cancer Institute, London, UK.
Jiang-Jiang QinDepartment of Gastric Surgery, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.
Minghao DangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xiuning LeDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-8554-1185
Can HuDepartment of Gastric Surgery, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.
Qing DengDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ansam SinjabDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-5777-227X
Pravesh GuptaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-1643-8950
Ruiping WangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Dapeng HaoDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-9043-371X
Fuduan PengDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xinmiao YanDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yunhe LiuDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-2120-952X
Shumei SongDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-8128-6287
Shaojun ZhangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-5760-5797
John V HeymachDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-9068-8942
Alexandre ReubenDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-4510-0382
Yasir Y ElaminDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-5312-909X
Melissa P PizziDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yang LuDepartment of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-9571-4679
Rossana LazcanoDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jian HuDepartment of Human Genetics, Emory School of Medicine, Atlanta, GA, USA.
Mingyao LiDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0001-8180-0621
Michael CurranDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-4996-7207
Andrew FutrealDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-8663-2671
Anirban MaitraDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-7923-9978
Amir A JazaeriDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-4335-4151
Jaffer A AjaniDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-9946-0629
Charles SwantonCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID 0000-0002-4299-3018
Xiang-Dong ChengDepartment of Gastric Surgery, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.
Hussein A AbbasDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-2946-3562
Maura GillisonDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Krishna BhatDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-2020-8509
Alexander J LazarDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-6395-4499
Michael GreenDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-6309-9472
Kevin LitchfieldTumour Immunogenomics and Immunosurveillance Laboratory, University College London Cancer Institute, London, UK.
Humam KadaraDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-2976-9115
Cassian YeeDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-4429-7307
Linghua WangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. LWang22@mdanderson.org.ORCID 0000-0001-9380-0266
The University of Texas MD Anderson Cancer Center · USChinese Academy of Sciences · CNCancer Research UK · GBEmory University · USLondon Cancer · GBThe Francis Crick Institute · GBUniversity of Pennsylvania · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MTumor cell lineage diversity and composition in gastric cancer progression and therapy resistanceR01CA266280 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Pawel K. Mazur, Linghua Wang · 2022 to 2026
$3.2MTranslational Genomics and Precision Medicine in Cancer Training ProgramT32CA217789 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Subrata Sen · 2018 to 2026
$2.2MSpatial and temporal tumor-immune co-evolution and interactions that model lung adenocarcinoma developmentU01CA264583 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Humam Kadara, Linghua Wang · 2022 to 2026
$2.1MMedical Research Council MR/V033077/1NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA266280NCI NIH HHS T32 CA217789NCI NIH HHS U01 CA264583Wellcome Trust CC2041
Abstract
Tumor-infiltrating T cells offer a promising avenue for cancer treatment, yet their states remain to be fully characterized. Here we present a single-cell atlas of T cells from 308,048 transcriptomes across 16 cancer types, uncovering previously undescribed T cell states and heterogeneous subpopulations of follicular helper, regulatory and proliferative T cells. We identified a unique stress response state, T
Indexed as
CD8-Positive T-LymphocytesNeoplasmsHumansImmune Checkpoint InhibitorsImmunotherapyLymphocytes, Tumor-InfiltratingTumor MicroenvironmentImmune Checkpoint Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.